Induced pluripotent cell-derived oligodendrocyte progenitor cells for the treatment of myelin disorders
AssigneeUniversity of Rochester
InventorsSteven A. GOLDMAN, Su WANG
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to a preparation of CD140a/PDGFRα positive cells that comprises oligodendrocyte progenitor cells co-expressing OLIG2 and CD140a/PDGFRα. The preparation of cells is derived from pluripotent cells that were derived from skin cells, fibroblasts, umbilical cord blood, peripheral blood, bone marrow, or other somatic cells. The cell preparation has an in vivo myelination efficiency that is equal to or greater than the in vivo myelination efficiency of a preparation of A2B5+/PSA-NCAM− sorted fetal human tissue derived oligodendrocyte progenitor cells. Methods of making, isolating and using the disclosed cell preparation are also described.
Claims61
A preparation of CD140a/PDGFRα positive cells wherein said preparation comprises oligodendrocyte progenitor cells co-expressing OLIG2 and CD140a/PDGFRα, and wherein said preparation of cells is derived from pluripotential cells derived from skin cells.
A preparation of CD140a/PDGFRα positive cells wherein said preparation comprises oligodendrocyte progenitor cells co-expressing OLIG2 and CD140a/PDGFRα, and wherein said preparation of cells is derived from pluripotential cells derived from umbilical cord blood.
A preparation of CD140a/PDGFRα positive cells wherein said preparation comprises oligodendrocyte progenitor cells co-expressing OLIG2 and CD140a/PDGFRα, and wherein said preparation of cells is derived from pluripotential cells derived from peripheral blood.
A preparation of CD140a/PDGFRα positive cells wherein said preparation comprises oligodendrocyte progenitor cells co-expressing OLIG2 and CD140a/PDGFRα, and wherein said preparation of cells is derived from pluripotential cells derived from bone marrow.
A preparation of cells at least 95% of which are CD140a/PDGFRα positive cells, wherein said preparation comprises oligodendrocyte progenitor cells co-expressing OLIG2 and CD140a/PDGFRα, and wherein said oligodendrocyte progenitor cells retain one or more epigenetic markers of a differentiated somatic cell other than an oligodendrocyte.
A method of producing an enriched preparation of oligodendrocyte progenitor cells said method comprising:
- culturing a population of induced pluripotent stem cells under conditions effective for said cells to form embryoid bodies;
- inducing cells of the embryoid bodies to differentiate into neuroepithelial cells and form neuroepithelial cell colonies;
- and
- exposing the neuroepithelial cell colonies to conditions effective to induce differentiation to oligodendrocyte progenitor cells, thereby forming an enriched preparation of oligodendrocyte progenitor cells co-expressing OLIG2 and CD140α/PDGFRα.
Dependencies are inferred from the claim text.